NASDAQ:GBTGlobal Blood Therapeutics Stock Price, Forecast & News

Global Blood Therapeutics' stock was trading at $54.85 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GBT stock has increased by 23.7% and is now trading at $67.83. View which stocks have been most impacted by Coronavirus.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Global Blood Therapeutics in the last year. There are currently 4 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Global Blood Therapeutics.

Global Blood Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Global Blood Therapeutics.

Global Blood Therapeutics Inc (NASDAQ:GBT) announced its quarterly earnings data on Wednesday, May, 6th. The company reported ($1.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.47) by $0.27. The firm had revenue of $14.12 million for the quarter, compared to analyst estimates of $3.65 million. During the same quarter in the prior year, the company earned ($0.87) EPS. View Global Blood Therapeutics' earnings history.

17 Wall Street analysts have issued 1-year price objectives for Global Blood Therapeutics' stock. Their forecasts range from $60.00 to $150.00. On average, they anticipate Global Blood Therapeutics' stock price to reach $105.00 in the next year. This suggests a possible upside of 54.8% from the stock's current price. View analysts' price targets for Global Blood Therapeutics.

News articles about GBT stock have trended negative recently, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Global Blood Therapeutics earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about Global Blood Therapeutics.

Global Blood Therapeutics saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 10,160,000 shares, an increase of 6.3% from the June 15th total of 9,560,000 shares. Based on an average daily trading volume, of 873,900 shares, the short-interest ratio is presently 11.6 days. Currently, 17.1% of the shares of the company are short sold. View Global Blood Therapeutics' Current Options Chain.

Some companies that are related to Global Blood Therapeutics include Merck KGaA (MKGAF), Beigene (BGNE), GALAPAGOS NV/S (GLPG), GRIFOLS S A/S (GRFS), Teva Pharmaceutical Industries (TEVA), Sarepta Therapeutics (SRPT), Catalent (CTLT), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Dr.Reddy's Laboratories (RDY), Ionis Pharmaceuticals (IONS), Elanco Animal Health (ELAN), Mylan (MYL), ACADIA Pharmaceuticals (ACAD) and Perrigo (PRGO). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Global Blood Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Cynosure (CYNO), TherapeuticsMD (TXMD), Exelixis (EXEL), AbbVie (ABBV), Advanced Micro Devices (AMD), Square (SQ) and Vertex Pharmaceuticals (VRTX).

(GBT) raised $102 million in an IPO on Wednesday, August 12th 2015. The company issued 6,000,000 shares at $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."

Shares of GBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of GBT stock can currently be purchased for approximately $67.83.

Global Blood Therapeutics has a market capitalization of $4.13 billion and generates $2.11 million in revenue each year. The company earns $-266,770,000.00 in net income (profit) each year or ($4.71) on an earnings per share basis. Global Blood Therapeutics employs 171 workers across the globe.

The official website for Global Blood Therapeutics is www.gbt.com.

Global Blood Therapeutics' mailing address is 181 OYSTER POINT BLVD, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-741-7700 or via email at [email protected]